Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.57
+0.09003.63%
Post-market: 2.620.0452+1.76%17:39 EDT
Volume:233.79K
Turnover:599.10K
Market Cap:38.86M
PE:-0.80
High:2.64
Open:2.54
Low:2.50
Close:2.48
52wk High:10.00
52wk Low:2.13
Shares:15.12M
Float Shares:9.60M
Volume Ratio:1.20
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1959
EPS(LYR):-2.9824
ROE:-107.62%
ROA:-60.80%
PB:1.69
PE(LYR):-0.86

Loading ...

CervoMed highlights late-breaking neflamapimod Phase 2a data

TIPRANKS
·
Yesterday

CervoMed Neflamapimod Phase 2a nfvPPA Biomarker Data Set for ISFTD 2026 Oral Session

Reuters
·
Sep 10

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026

THOMSON REUTERS
·
Sep 10

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

GlobeNewswire
·
Sep 10

CervoMed to Participate in September Investor Conferences

GlobeNewswire
·
Sep 08

CervoMed price target lowered to $7 from $9 at Roth Capital

TIPRANKS
·
Aug 20

CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 12

CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained

TIPRANKS
·
Aug 12

CervoMed is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Aug 10

CervoMed Q2 Net Loss Lower than Estimates as Costs Drop

Reuters
·
Aug 10

CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate

Benzinga Earnings
·
Aug 10

Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 10

CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None

Reuters
·
Aug 08

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

GlobeNewswire
·
Aug 05

CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview

Reuters
·
Aug 04

CervoMed’s neflamapimod gains UK Innovation Passport

TIPRANKS
·
Aug 04

CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia

Reuters
·
Aug 04

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)

THOMSON REUTERS
·
Aug 04

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 15